Table 1 Randomized studies included in analysis

ORT

placebo

Peru

3–35

67–68

DB, HB, boys only

[40]

ORT

placebo

France

3–48

82–84

DB, HB

[38]

ORT

placebo

India

< 60

30

DB, HB, ABS

[42]

ORT or IRT

placebo

China

< 24

39

DB, HB

[44]

ORT and/or IRT, zinc

placebo

Kenya

3–60

57–58

DB, HB

[39]

ORT

placebo

Ecuador

3–36

34–45

SB, HB

[35]

ORT or IRT

–

France

3–36

81–83

HB

[36]

ORT or IRT

–

China

4–36

24–36

HB

[45]

ORT

–

Spain

3–36

70–78

HB

[33]

ORT

–

China

3–36

24

Setting n.r.

[46]

ORT

–

Spain

3–36

94

HB

[34]

ORT

–

Egypt

12–72

30

HB

[41] study I

ORT

–

Egypt

12–72

15

OB

[41] study IIc

ORT, smectite

–

China

1–30

30–35

HB

[47]

ORT, smectite

–

China

6–11

58

OB

[48]

ORT or IRT, smectite

–

China

2–36

89

HB, 3-armed

[30]

ORT, smectite

–

China

3–36

124–134

HB, OB

[49]

ORT, smectite

–

China

3–36

50–60

Setting n.r.

[50]

ORT, smectite, PB

–

China

2–36

43–53

HB, OB, 3-armed

[29]

ORT, smectite, PB

–

China

4–27

113–165

Setting n.r.

[51]

ORT, smectite, PB

–

China

3–36

60

Setting n.r.

[53]

ORT, smectite, PB

–

China

6–24

59–62

Setting n.r.

[54]

ORT, smectite, PB

–

China

3–36

30–34

Setting n.r.

[55]

ORT, smectite, PB

–

China

< 24

50

Setting n.r.

[56]

ORT, smectite, PB

–

China

5–27

22–43

Setting n.r.

[52]

ORT, smectite, PB

–

China

2–36

57–68

HB

[57]

ORT, smectite, PB

–

China

2–24

50

Setting n.r.

[58]

ORT or IRT, smectite, PB

–

China

5–24

53

HB

[59]

ORT, smectite, PB

–

China

2–36

56

OB and HB

[60]

ORT or IRT, smectite, PB

–

China

4–24

40

HB

[61]

ORT, smectite, PB

–

China

1–24

43–45

HB

[62]

ORT, smectite, PB

China

3–24

52–56

HB

[63]

ORT, smectite, PB

–

China

6–24

28–30

OB

[64]

IRT, AV

–

China

6–36

48–54

HB

[66]

ORT or IRT, AV

–

China

6–48

40

HB, 4-armed

[31]

ORT or IRT, AV

–

China

2–36

66–69

HB

[67]

ORT, smectite, ribaverine

–

China

6–24

50

Setting n.r.

[65]

ORT, smectite, AV

–

China

18*

56

HB

[68]

ORT, PB, AV

–

China

1–24

38–42

Setting n.r.

[69]

ORT, PB, AV

–

China

3–24

52–68

Setting n.r.

[70]

ORT or IRT, smectite, PB, AV

–

China

6–36

36–44

OB and HB

[71]

ORT, AV, AIN

–

China

7–36

69

Setting n.r.

[72]

ORT, nitazoxanide

–

Egypt

12–72

15

OB

[41] study IIa

ORT, metronidazole

–

Egypt

12–72

15

OB

[41] study IIb

ORT, PB, AI

–

China

12–60

43

HB

[73]

ORT, AI

–

China

6–24

50

OB and HB, 4-armed

[32]

Not fully specified

–

China

4–36

60

HB

[74]

Loperamide

France

24–120

50–52

DB, setting n.r.

[37]

ORT, IRT, PB

Smectite

China

6–24

60

HB

[79]

ORT

Smectite

China

1–36

150

HB

[77]

ORT or IRT

smectite

China

2–36

89

HB, 3-armed

[30]

IRT, PB

smectite

China

6–24

42–44

HB

[78]

ORT, PB, (AB)

Smectite

China

2–60

56–58

OB

[76]

ORT

PB

China

4–24

50

Setting n.r.

[81]

ORT or IRT, AV

PB

China

6–48

40

HB, 4-armed

[31]

IRT

PB

China

6–24

40–42

Setting n.r.

[80]

ORT, AI

PB

China

6–24

50

OB and HB, 4-armed

[32]

ORT

Smectite + PB

China

2–24

41–43

Setting n.r.

[83]

ORT

Smectite + PB

China

2–36

43–53

HB, OB, 3-armed

[29]

ORT or IRT, AV

Smectite + PB

China

2–36

56

HB, OB

[82]

ORT

Kaolin/pectin

Guatemala

3–71

25

OB

[84]

ORT, PB, smectite

Lactose-free diet

China

4–36

34–38

OB, 3-armed

[85]